SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes
Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 ...
Model output · Signal date 2026-10-14
Sab Biotherapeutics, Inc. (SABS) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Alpha
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Middle 30%
of 4004 stocks scored
Rank correlation · 90D
n/a
No per-ticker sample yet
Market Cap
$244M
small-cap · #60 of 60 peers
Summary
Sab Biotherapeutics, Inc. (SABS) stock forecast summary
On Oct. 14, 2026, SABS is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 4004 stocks scored that day.
Sab Biotherapeutics, Inc. is a small-cap company with a market capitalization of $244M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its P/B Ratio of 1.14x is the lowest of the 50 peers that report one.
A per-ticker accuracy statistic for SABS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.2%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SABS included.
Follow SABS freePrice
SABS price chart and AI forecast
Cross-section · 2026-10-14
How SABS ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals
Sab Biotherapeutics, Inc. (SABS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | SABS | Rank |
|---|---|---|
| Market Cap | $244M | 60/60 |
| P/B Ratio | 1.14x | 50/50 |
| EPS | $0.02 | – |
| Book Value/Share | $2.36 | – |
Profitability & Margins
| Metric | SABS | Rank |
|---|---|---|
| ROIC | -31.7% | 25/50 |
| Operating Margin | 6571.2% | 1/37 |
| EBT Margin | 878.0% | 1/38 |
Financial Health
| Metric | SABS | Rank |
|---|---|---|
| Current Ratio | 9.22x | 17/54 |
| D/E Ratio | 0.11x | 43/50 |
| Financial Leverage | 1.11x | 43/50 |
| Interest Coverage | -377.0x | 28/38 |
| Working Capital | $96M | 50/54 |
Cash Flow
| Metric | SABS | Rank |
|---|---|---|
| Operating Cash Flow | -$54M | 23/52 |
Income Statement
| Metric | SABS | Rank |
|---|---|---|
| Operating Income | -$71M | 16/50 |
| R&D Expense | $49M | 47/51 |
Dividend & Shareholder Information
| Metric | SABS | Rank |
|---|---|---|
| Shares Outstanding | 91M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $108M | 45.5% of assets |
| Cash & Short-term Investments | $8M | 3.5% of assets |
| Total Liabilities | $23M | 9.9% of assets |
| Short-term Debt | $8M | 3.3% of assets |
Quarterly Financial Reports
SABS quarterly financials and insider trading
Industry Peers · Biological Products, (No Diagnostic Substances)
Sab Biotherapeutics, Inc. (SABS) industry peers
Companies classified under the same SEC industry code as Sab Biotherapeutics, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| SABS Sab Biotherapeutics, Inc. | ▶ | $244M |
| AMGN Amgen Inc | ▼ | $223.19B |
| GILD Gilead Sciences, Inc. | ▶ | $183.41B |
| MRNA Moderna, Inc. | ▲ | $86.33B |
| ARGX Argenx Se | ▶ | $49.67B |
| RVMD Revolution Medicines, Inc. | ▲ | $40.39B |
| BIIB Biogen Inc. | ▼ | $33.79B |
| BNTX Biontech Se | ▶ | $22.51B |
| MESO Mesoblast Ltd | ▼ | $18.02B |
| EXEL Exelixis, Inc. | ▲ | $14.75B |
| NBIX Neurocrine Biosciences Inc | ▼ | $13.74B |
| HALO Halozyme Therapeutics, Inc. | ▲ | $12.44B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| IBRX Immunitybio, Inc. | ▲ | $10.39B |
| PCVX Vaxcyte, Inc. | ▲ | $9.94B |
| RGEN Repligen Corp | ▲ | $9.90B |
| QGEN Qiagen N.V. | ▼ | $9.86B |
| KRYS Krystal Biotech, Inc. | ▲ | $9.51B |
| TWST Twist Bioscience Corp | ▲ | $9.49B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.87B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.57B |
| IMVT Immunovant, Inc. | ▲ | $5.93B |
| KOD Kodiak Sciences Inc. | ▲ | $5.76B |
| CGON Cg Oncology, Inc. | ▲ | $5.53B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.93B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.03B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.80B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.11B |
| DNLI Denali Therapeutics Inc. | ▲ | $2.94B |
| DBVT Dbv Technologies S.A. | ▼ | $2.67B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.52B |
| ADMA Adma Biologics, Inc. | ▲ | $2.31B |
| NVAX Novavax Inc | ▲ | $2.11B |
| VCEL Vericel Corp | ▶ | $2.06B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.05B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.80B |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.71B |
| ALVO Alvotech | ▶ | $1.68B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.48B |
| IMCR Immunocore Holdings Plc | ▲ | $1.43B |
| COAG Hemab Therapeutics Holdings, Inc. | ▲ | $1.39B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.17B |
| REPL Replimune Group, Inc. | ▲ | $1.14B |
| VOR Vor Biopharma Inc. | ▶ | $1.13B |
| JATT Zura Bio Ltd | ▼ | $1000M |
| VALN Valneva Se | ▼ | $965M |
| MGTX Meiragtx Holdings Plc | ▶ | $955M |
| IMTX Immatics N.V. | ▶ | $916M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $907M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $844M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $829M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $792M |
| SANA Sana Biotechnology, Inc. | ▶ | $721M |
| CADL Candel Therapeutics, Inc. | ▲ | $709M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $682M |
| AURA Aura Biosciences, Inc. | ▲ | $650M |
| SLDB Solid Biosciences Inc. | ▲ | $624M |
| PRME Prime Medicine, Inc. | ▲ | $602M |
Where SABS sits on the market map
Life Sciences · Biological Products, (No Diagnostic Substances)
News
Sab Biotherapeutics, Inc. (SABS) stock news
SAB Biotherapeutics, Inc. (SABS) Q1 2026 Earnings Call Transcript
Good morning, and welcome to the SAB Bio's conference call to discuss first quarter 2026 financial results and business updates. Listeners are invited to review the full text of the forward-looking ...
SAB Bio Wins FDA Fast Track Status For SAB-142 In Type 1 Diabetes; Stock Up
SAB Biotherapeutics, Inc. announced that the U.S. FDA has granted Fast Track designation to SAB-142 for the treatment of patients with Stage 3 Type 1 Diabetes. The designation is ...
FAQ
Sab Biotherapeutics, Inc. (SABS) stock forecast FAQ
What is the Sab Biotherapeutics, Inc. (SABS) stock forecast?
On Oct. 14, 2026, SABS is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 4004 stocks scored that day.
How accurate are Sab Biotherapeutics, Inc. stock predictions?
A per-ticker accuracy statistic for SABS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Sab Biotherapeutics, Inc. forecasts updated?
Sab Biotherapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Sab Biotherapeutics, Inc.'s industry peers?
60 issuers in our coverage, SABS included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.